Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 4:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 44 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Antibody-mediated Rejection Clear all
Terminated Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Kidney Transplant
Interventions
Eculizumab
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 19, 2015 · Synced May 22, 2026, 4:10 AM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Antibody-mediated Rejection, Kidney Transplant; Complications, Transplant Glomerulopathy, Transplant Glomerulopathy - Late Form, Transplant Glomerulopathy - Early Form, Kidney Transplant Rejection
Interventions
Clazakizumab
Drug
Lead sponsor
Stanley Jordan, MD
Other
Eligibility
15 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 5, 2025 · Synced May 22, 2026, 4:10 AM EDT
Terminated Phase 3 Interventional Results available
View directory record Official record
Conditions
Acute Antibody-Mediated Rejection (AMR)
Interventions
Cinryze®, Placebo
Biological · Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 70 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
29
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2020 · Synced May 22, 2026, 4:10 AM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Lung Transplant Rejection
Interventions
Lung transplant biopsy bites.
Procedure
Lead sponsor
University of Alberta
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
4
States / cities
Phoenix, Arizona • Baltimore, Maryland • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced May 22, 2026, 4:10 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Antibody Mediated Rejection of Kidney Transplant
Interventions
C1-INH (Berinert)
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 10, 2019 · Synced May 22, 2026, 4:10 AM EDT
Withdrawn Early Phase 1 Interventional
View directory record Official record
Conditions
Antibody-mediated Rejection, Allosensitization
Interventions
Isatuximab, bone marrow biopsy
Drug · Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced May 22, 2026, 4:10 AM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
Carfilzomib, Belatacept
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
10
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced May 22, 2026, 4:10 AM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Kidney Transplantation
Interventions
C1 Esterase Inhibitor, Placebos
Drug
Lead sponsor
Stanley Jordan, MD
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced May 22, 2026, 4:10 AM EDT
Terminated Phase 3 Interventional Results available
View directory record Official record
Conditions
Antibody-mediated Rejection
Interventions
C1-esterase inhibitor, Placebo
Drug
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
13
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced May 22, 2026, 4:10 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Graft Rejection
Interventions
Placebo, C1 Esterase Inhibitor (Human)
Biological
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced May 22, 2026, 4:10 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Lung Transplant Rejection
Interventions
Carfilzomib
Drug
Lead sponsor
John F. McDyer, MD
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 24, 2022 · Synced May 22, 2026, 4:10 AM EDT
Terminated Phase 4 Interventional Results available
View directory record Official record
Conditions
Transplant Glomerulopathy
Interventions
Acthar gel
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
2
States / cities
Birmingham, Alabama • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2022 · Synced May 22, 2026, 4:10 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Antibody-mediated Rejection, Hyperacute Rejection of Cardiac Transplant, Left Ventricular Dysfunction, Cardiac Allograft Vasculopathy, Heart Graft Dysfunction
Interventions
Eculizumab
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 2, 2021 · Synced May 22, 2026, 4:10 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Kidney Transplant Failure and Rejection
Interventions
AlloSure ddcfDNA assay, AlloMap assay, Inflammatory Cytokines, Immune Cell Phenotypes
Diagnostic Test
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 2, 2024 · Synced May 22, 2026, 4:10 AM EDT
Withdrawn Phase 4 Interventional
View directory record Official record
Conditions
End Stage Renal Disease, Antibody Mediated Rejection
Interventions
Belatacept, Tacrolimus withdrawal, Plasmapheresis/Intravenous Immunoglobulin G, Thymoglobulin (ATG), Myfortic, Steroids
Drug · Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 16, 2018 · Synced May 22, 2026, 4:10 AM EDT
Completed No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
Kidney; Complications, Allograft, Transplantation Infection
Interventions
Immunosuppressive Agents
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
2 Years to 85 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2023
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated May 18, 2023 · Synced May 22, 2026, 4:10 AM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Renal Disease
Interventions
IdeS® (Imlifidase)
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 15, 2022 · Synced May 22, 2026, 4:10 AM EDT
Enrolling by invitation Phase 3 Interventional
View directory record Official record
Conditions
Antibody-mediated Rejection
Interventions
Felzartamab
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
2
States / cities
Los Angeles, California • West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced May 22, 2026, 4:10 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Kidney Failure, Chronic, End-Stage Renal Disease, Transplant Glomerulopathy, Transplant;Failure,Kidney, Kidney Transplant Failure and Rejection, Antibody-mediated Rejection, Kidney Transplant; Complications
Interventions
Clazakizumab
Drug
Lead sponsor
Stanley Jordan, MD
Other
Eligibility
15 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 23, 2025 · Synced May 22, 2026, 4:10 AM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Kidney Transplant
Interventions
Low dose adipose tissue derived mesenchymal stromal cells (A-MSC), High dose adipose tissue derived mesenchymal stromal cells (A-MSC)
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced May 22, 2026, 4:10 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
Imlifidase, Plasma Exchange
Drug · Other
Lead sponsor
Hansa Biopharma AB
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
4
States / cities
Los Angeles, California • Boston, Massachusetts • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2024 · Synced May 22, 2026, 4:10 AM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Antibody Mediated Rejection of Lung Transplant
Interventions
Siltuximab, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
St Louis, Missouri • Saint Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced May 22, 2026, 4:10 AM EDT
Active, not recruiting No phase listed Observational
View directory record Official record
Conditions
Renal Transplant Rejection, Pediatric Kidney Disease, End Stage Renal Disease, Nephropathy, BK Virus (Nephropathy), Antibody-mediated Rejection, Acute Cellular Graft Rejection
Interventions
Not listed
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Years to 18 Years
Enrollment
445 participants
Timeline
2017 – 2026
U.S. locations
12
States / cities
La Jolla, California • Los Angeles, California • Palo Alto, California + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced May 22, 2026, 4:10 AM EDT
Not yet recruiting Phase 1 Interventional
View directory record Official record
Conditions
Lung Transplantation
Interventions
fostamatinib, Placebo
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
5
States / cities
Stanford, California • Baltimore, Maryland • Bethesda, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced May 22, 2026, 4:10 AM EDT